XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUE
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three and nine months ended September 30, 2023 and 2022 were as follows:
Three Months EndedNine Months Ended
(in millions)2023202220232022
Equipment & Instruments$148 $163 $480 $498 
CAD/CAM128 123 370 377 
Connected Technology Solutions$276 $286 $850 $875 
Essential Dental Solutions$347 $348 $1,110 $1,084 
Orthodontics$83 $76 $255 $220 
Implants & Prosthetics169 171 526 552 
Orthodontic and Implant Solutions$252 $247 $781 $772 
Wellspect Healthcare$72 $66 $212 $208 
Total net sales$947 $947 $2,953 $2,939 

Net sales disaggregated by geographic region for the three and nine months ended September 30, 2023 and 2022 were as follows:
Three Months EndedNine Months Ended
(in millions)2023202220232022
United States$356 $357 $1,069 $1,023 
Europe354 358 1,153 1,183 
Rest of World237 232 731 733 
Total net sales$947 $947 $2,953 $2,939 

Contract Assets and Liabilities

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had deferred revenue of $87 million and $54 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at September 30, 2023. The Company had deferred revenue of $91 million and $27 million recorded in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2022. The Company recognized approximately $59 million of revenue during the current year which was previously deferred as of December 31, 2022. The Company expects to recognize a majority of the remaining deferred revenue within the next twelve months.
Allowance for Doubtful Accounts

Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $13 million at September 30, 2023 and $14 million at December 31, 2022. For the three and nine months ended September 30, 2023 and 2022, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.